Rethinking Clinical Trials

JULY 13, 2023

In modeling exercises, optimal implementation of these therapies, such as an ARNI, a beta blocker, an MRA, and an SGLT2 inhibitor, compared to conventional therapy (an ACEi or ARB plus a beta blocker) is estimated to afford more than 6 years of survival in a typical 55-year-old patient. Learn more Read about the IMPLEMENT-HF study in JACC.

Clinical Trials 130

Clinical Trials Clinical Trials Scientist Research 130

Rethinking Clinical Trials

NOVEMBER 16, 2022

But if PCTs use a waiver/alteration of consent, the trial cannot assume sharing data is consistent with preferences of patient-subjects and cannot rely on informed consent to fulfill the ethical obligation of respect. For PCTs, data volume is potentially larger, data may be “about” those beyond patient-subjects (i.e.

Clinical Trials 246

Clinical Trials Clinical Trials Trials Research 246

Rethinking Clinical Trials

MARCH 6, 2024

The dietician met with the patient to share education about nutrition, portion size, recipes to make food taste good, and information via an optional diabetes self-management program. 500 patients were randomized to intervention or control groups, with a utilization of 465 and 349 participants completing the 6-month HbA1c lab sample.

Clinical Trials 143

Clinical Trials Clinical Trials Medicine Trials 143

Rethinking Clinical Trials

SEPTEMBER 16, 2022

Dr. Joffe and his collaborators conducted a preliminary study of qualitative interviews, funded by PCORI, with 99 leaders of 16 geographically diverse Learning Health Systems. How are patients and families included in governance of learning within your LHS? From these questions three main challenges emerged. Learn more.

Clinical Trials 100

Clinical Trials Clinical Trials Trials Research 100

Rethinking Clinical Trials

FEBRUARY 9, 2023

This trial tested the hypothesis that the use of a platform-agnostic, EHR-embedded VTE risk model with integrated CDS would 1) increase rates of appropriate Thromboprophylaxis, and subsequently 2) reduce thromboembolism, compared to usual medical care in hospitalized, medically-ill patients.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Development 130

Intouch Solutions

APRIL 11, 2024

Commercial : Improved experience and communication between patients and doctors. In the pharma industry, precision engagement can be used to present patients, healthcare professionals (HCPs), and other stakeholders with relevant information and support at the right time. It uses customer insights to deliver personalized experiences.

Compliance 52

Compliance Marketing Drugs Pharma Companies 52

pharmaphorum

AUGUST 17, 2020

In this article Joanna Carlish, managing director of financial services at Tag Americas , and Robb DeFilippis, Tag Americas’ managing director, life sciences, go head-to-head to discuss marketing within a regulated industry. Virtual connections. Engagement channels. Regulated industry learnings.

Regulation 87

Regulation Marketing Sales Branding 87

The Pharma Data

OCTOBER 9, 2021

This designation is predicated on data showing that gantenerumab significantly reduced brain amyloid pillar, a pathological hallmark of Notice, in the ongoing SCarlet RoAD and Marguerite RoAD open- tag extension trials, as well as other studies.

Antibody 52

Antibody In-Vitro Trials Development 52

Rethinking Clinical Trials

FEBRUARY 2, 2023

There are many choices clinicians must make for every emergency tracheal intubation for which the effect on patient outcomes is unknown. The data collector was not clinically taking care of the patient but familiar with the procedure and trained on data collection. It is an important procedure and is also challenging to research.

Trials 130

Trials Clinical Trials Clinical Trials Medicine 130

XTalks

AUGUST 17, 2020

Suri explains that in the case of cancer immunotherapy, the conventional “carpet bombing” approaches of broadly activating the immune system — or in cases of autoimmunity, broadly immunosuppressing it — has implications for patient safety. There is great unmet need in head and neck cancer as patients don’t have a lot of treatment options.

Protein 98

Protein Engineer Immune Response In-Vivo 98

XTalks

MARCH 22, 2023

In October 2022, Xtalks celebrated two decades of bringing diverse stakeholders in the life science industry together through first holding physical events, then soon after, hosting exclusively online events. More potential patients equal more prescriptions which equals higher sales and bigger profits.

Life Science 97

Life Science Drugs FDA Approval Vaccination 97

Drug Discovery World

NOVEMBER 13, 2023

Noel Pauli, PhD, Group Leader, Antibody Engineering, Adimab, on: ‘Harnessing in vivo diversities with a yeast-based platform for the discovery of antibodies against multi-pass membrane proteins’. Jendrik Schöppe, PhD, Senior Scientist, Novo Nordisk, on: ‘Stablised GPCRs for antibody discovery’.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

NOVEMBER 9, 2023

These include: Xiaole Shirley Liu, PhD, CEO, GV20 Therapeutics, on: ‘AI-based target and antibody discovery from patient tumour profiles’. Jorge Dias, PhD, Principal Scientist, Alchemab Therapeutics, on: ‘A patient-first approach to discover first-in-class antibody therapeutics’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Rethinking Clinical Trials

NOVEMBER 9, 2022

The mission is to democratize cardiovascular education by creating and disseminating education, fostering wellness and humanism, promoting diversity, equity and inclusion, providing mentorship and sponsorship, and invigorating a love of cardiovascular science. The fellows were responsible for 45% of enrollment during the time of the trial.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Development 130

Rethinking Clinical Trials

OCTOBER 31, 2023

Does it capture most what matters to patients? – How do you organize recruitment to ensure you have the diversity you want and how do you explain to people you are turning away? We had to operate the trial with an institution that would allow zero risk. We had to come up with solutions. Pfizer provided feedback.

Trials 229

Trials Medicine Research Clinical Trials 229

The Pharma Data

MAY 4, 2021

Each of these accomplishments further demonstrates our commitment to Pfizer’s purpose: Breakthroughs that change patients’ lives.”. I remain confident in Pfizer’s ability to continue to deliver on our commitments to our patients and shareholders in 2021 and beyond.”. This will make 2021 the 12th year in a row with a dividend increase.

Vaccination 40

Vaccination Vaccine Production Sales 40